BET inhibitors RVX-208 and PFI-1 reactivate HIV-1 from latency

Panpan Lu1, Yinzhong Shen2, He Yang1

  • 1State Key Laboratory of Genetic Engineering, Institute of Genetics, School of Life Sciences, Fudan University, Shanghai, 200438, China.

Scientific Reports
|December 2, 2017
PubMed

Insights

Two BET inhibitors, RVX-208 and PFI-1, effectively reactivate latent HIV-1 (Human Immunodeficiency Virus type 1) by up-regulating P-TEFb. This finding offers a promising strategy for HIV-1 reservoir eradication.

Area of Science:

  • Virology
  • Immunology
  • Pharmacology

Background:

  • The persistent latent reservoir in resting CD4+ T cells is a significant barrier to curing HIV-1 infection.
  • Developing effective strategies for HIV-1 reservoir eradication is a critical research priority.

Purpose of the Study:

  • To investigate the potential of BET inhibitors, RVX-208 and PFI-1, in reactivating latent HIV-1.
  • To explore the mechanism by which these BET inhibitors reverse HIV-1 latency.

Main Methods:

  • Treatment of latently infected Jurkat T cells and ex vivo patient-derived resting CD4+ T cells with BET inhibitors RVX-208 and PFI-1.
  • Assessment of HIV-1 transcription reactivation and P-TEFb pathway modulation, including CDK9 Thr-186 phosphorylation.
  • Evaluation of global immune cell activation.

Main Results:

  • RVX-208 and PFI-1 demonstrated the ability to reactivate HIV-1 transcription from latency, both individually and in combination with other latency-reversing agents.
  • The reactivation mechanism involves up-regulation of P-TEFb via increased CDK9 Thr-186 phosphorylation.
  • HIV-1 reactivation was observed in ex vivo settings using patient-derived cells without inducing global immune cell activation.

Conclusions:

  • BET inhibitors RVX-208 and PFI-1 are effective in reactivating latent HIV-1.
  • These compounds represent a promising therapeutic avenue for targeting the HIV-1 reservoir and achieving viral eradication.

Related Concept Videos

Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
868
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
49.8K
Retroviruses02:33

Retroviruses

Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.0K